Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Research save search
Italian Government Clears Merger Plan of Dragon SPAC S.p.A. and Jaguar Health's Italian Subsidiary Napo EU S.p.A. for Closing
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
JAGX | $0.1637 -8.19% -8.92% 130M
|
Health Technology
|
| O: 8.38%
H: 3.86%
C: -2.42%
spac merge
The Merger of Dragon SPAC S.p.A. and Napo EU S.p.A. has Closed
Published: 2021-11-01 (Crawled : 13:00) - biospace.com/
JAGX | $0.1637 -8.19% -8.92% 130M
|
Health Technology
|
| O: 2.11%
H: 0.0%
C: 0.0%
spac merge
Jaguar Health Completes Filing of New Animal Drug Application for Conditional Approval of Canalevia-CA1 (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs, Clearing Way for December 2021 Launch
Published: 2021-11-02 (Crawled : 13:00) - biospace.com/
JAGX | $0.1637 -8.19% -8.92% 130M
|
Health Technology
|
| O: -1.15%
H: 0.47%
C: -3.72%
diarrhea application therapy drug approval crofelemer
Jaguar Health Provides Corporate Update and Outlines 2022 Milestones
Published: 2022-01-13 (Crawled : 14:00) - biospace.com/
JAGX | $0.1637 -8.19% -8.92% 130M
|
Health Technology
|
| O: -6.67%
H: 1.27%
C: -3.06%
health milestone
Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2022-01-04 (Crawled : 01:00) - biospace.com/
JAGX | $0.1637 -8.19% -8.92% 130M
|
Health Technology
|
| O: 3.74%
H: 0.0%
C: 0.0%
treatment health diarrhea therapy crofelemer
Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
Published: 2022-10-26 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.1637 -8.19% -8.92% 130M
|
Health Technology
|
| O: -0.35%
H: 2.85%
C: 2.56%
treatment research diarrhea breast health crofelemer cancer publication study
Jaguar Health Announces Launch of Mytesi Telehealth Program
Published: 2022-05-11 (Crawled : 14:00) - biospace.com/
JAGX | $0.1637 -8.19% -8.92% 130M
|
Health Technology
|
| O: -2.48%
H: 2.54%
C: -1.54%
health program
Canine and Child Cancer Research Advocates Call for Support as Capitol Hill "Goes to the Dogs"
Published: 2023-06-08 (Crawled : 19:00) - jaguarhealth.gcs-web.com
JAGX | $0.1637 -8.19% -8.92% 130M
|
Health Technology
|
| O: 1.98%
H: 0.0%
C: -2.69%
cancer research
Napo Pharmaceuticals Supports Groundbreaking Study on Quality of Life for Cancer Patients and Survivors
Published: 2023-09-26 (Crawled : 13:00) - biospace.com/
JAGX | $0.1637 -8.19% -8.92% 130M
|
Health Technology
|
| O: 0.19%
H: 3.51%
C: -2.33%
life cancer pharmaceuticals study
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHD
Published: 2023-09-21 (Crawled : 12:00) - biospace.com/
JAGX | $0.1637 -8.19% -8.92% 130M
|
Health Technology
|
| O: -0.28%
H: 4.8%
C: 2.03%
health research adhd
First U.S.-Based Canine Cancer Registry, Founded by Jaguar Health, Joins International Network to Help Advance Canine and Human Cancer Research
Published: 2023-06-26 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.1637 -8.19% -8.92% 130M
|
Health Technology
|
| O: -0.19%
H: 2.86%
C: 2.6%
cancer international research network
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
Published: 2023-12-06 (Crawled : 14:30) - biospace.com/
JAGX | $0.1637 -8.19% -8.92% 130M
|
Health Technology
|
| O: 0.03%
H: 1.67%
C: -1.27%
breast health life symposium cancer pharmaceuticals family study
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
JAGX | $0.1637 -8.19% -8.92% 130M
|
Health Technology
|
| O: 26.26%
H: 73.2%
C: 18.87%
health cancer care for commercial
China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin
Published: 2022-01-14 (Crawled : 21:00) - biospace.com/
SXTC | $1.165 -28.09% -31.71% 2.2M
|
Health Technology
|
| O: 16.87%
H: 0.0%
C: 0.0%
als ces china growth
Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression
Published: 2023-09-18 (Crawled : 14:00) - globenewswire.com
KA A | $0.481 0.27% 0.27% 730K
|
Manufacturing
|
| O: 15.03%
H: 2.7%
C: -0.45%
biomarker research agreement
Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous System Disorders
Published: 2021-10-22 (Crawled : 13:00) - biospace.com/
PALI | $6.54 10.29% 9.33% 1.6M
|
Manufacturing
|
| O: 1.43%
H: 0.0%
C: -8.1%
nervous system treatment
Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide Preparation for Late-Stage Clinical Trials of LB1148
Published: 2021-06-15 (Crawled : 13:00) - biospace.com/
PALI | $6.54 10.29% 9.33% 1.6M
|
Manufacturing
|
| O: 0.95%
H: 0.94%
C: -5.16%
clinical trials trial
BioSig’s Division NeuroClear Technologies Signs a Research Agreement with the University of Minnesota
Published: 2020-12-18 (Crawled : 14:01) - globenewswire.com
BSGM | $1.63 7.95% 7.36% 4M
|
Health Technology
|
| O: 0.65%
H: 4.32%
C: -3.46%
research
BioSig’s Division NeuroClear Technologies Signs a Research Agreement with the University of MinnesotaNeuroClear is set to commence experiments aimed at developing therapies for autonomic nervous system disease
Published: 2020-12-18 (Crawled : 15:00) - biospace.com/
BSGM | $1.63 7.95% 7.36% 4M
|
Health Technology
|
| O: 0.65%
H: 4.32%
C: -3.46%
disease nervous system therapy research
BioSig Issues Shareholder Update to Highlight Recent Achievements and Ongoing Developments
Published: 2023-01-19 (Crawled : 14:20) - biospace.com/
BSGM | $1.63 7.95% 7.36% 4M
|
Health Technology
|
| O: -0.03%
H: 5.63%
C: 4.23%
ongoing update
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.